Nkarta Book Value 2011-2026 | NKTX

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value Nkarta

2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
273 M	372 M	251 M	321 M	-25.5 M	-5.4 M	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
372 M	-25.5 M	198 M

Quarterly Book Value Nkarta

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
338 M	358 M	379 M	431 M	453 M	474 M	297 M	318 M	347 M	372 M	399 M	421 M	229 M	251 M	270 M	288 M	306 M	321 M	321 M	321 M	-	34.3 M	34.3 M	34.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
474 M	34.3 M	304 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
I-Mab IMAB	5.63 B	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Apellis Pharmaceuticals APLS	370 M	$ 20.7	-1.24 %	$ 2.61 B	USA
Aptorum Group Limited APM	11.8 M	$ 0.84	7.59 %	$ 4.58 M	China
Biophytis SA BPTS	34.9 M	-	-13.47 %	$ 169 M	France
Axsome Therapeutics AXSM	88.3 M	$ 166.38	1.52 %	$ 8.28 B	USA
AbCellera Biologics ABCL	967 M	$ 3.82	5.82 %	$ 1.14 B	Canada
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	8.32 M	-	-18.52 %	$ 27.3 M	Britain
Burford Capital Limited BUR	1.66 B	$ 8.73	3.44 %	$ 1.37 B	Britain
Capricor Therapeutics CAPR	22.6 M	$ 26.86	-3.83 %	$ 719 M	USA
Codexis CDXS	66.9 M	$ 1.02	0.99 %	$ 74.9 M	USA
Adverum Biotechnologies ADVM	70.7 M	-	-	$ 86.2 M	USA
Институт стволовых клеток человека ISKJ	10.6 M	-	-	-	Russia
Cellectis S.A. CLLS	131 M	$ 3.8	-2.06 %	$ 116 M	France
ARCA biopharma ABIO	382 M	-	1052.0 %	$ 415 M	USA
Acer Therapeutics ACER	-16.8 M	-	2.71 %	$ 14 M	USA
Alpine Immune Sciences ALPN	179 M	-	-	$ 2.17 B	USA
CNS Pharmaceuticals CNSP	6.18 M	$ 3.13	-0.95 %	$ 1.2 M	USA
Acorda Therapeutics ACOR	109 M	-	-24.86 %	$ 820 K	USA
Collegium Pharmaceutical COLL	302 M	$ 41.6	-0.17 %	$ 1.32 B	USA
Corcept Therapeutics Incorporated CORT	648 M	$ 35.97	0.76 %	$ 3.74 B	USA
Catalyst Pharmaceuticals CPRX	954 M	$ 23.88	3.47 %	$ 2.92 B	USA
Acasti Pharma ACST	66.6 M	-	4.01 %	$ 150 M	Canada
Corbus Pharmaceuticals Holdings CRBP	-6.9 M	$ 8.35	-2.57 %	$ 36.1 M	USA
Curis CRIS	-6 M	$ 1.08	-5.26 %	$ 6.81 M	USA
Crinetics Pharmaceuticals CRNX	992 M	$ 40.68	-1.02 %	$ 3.83 B	USA
Corvus Pharmaceuticals CRVS	38.7 M	$ 17.89	-2.03 %	$ 859 M	USA
Champions Oncology CSBR	3.77 M	$ 6.07	2.71 %	$ 82.9 M	USA
Citius Pharmaceuticals CTXR	74.1 M	$ 0.72	-2.3 %	$ 4.84 M	USA
CEL-SCI Corporation CVM	12.9 M	$ 3.83	-10.09 %	$ 244 M	USA
CureVac N.V. CVAC	688 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	13.2 M	-	5.93 %	$ 314 M	Canada
Daré Bioscience DARE	-6.01 M	$ 1.61	-5.29 %	$ 13.7 M	USA
DBV Technologies S.A. DBVT	27.4 M	$ 23.25	10.77 %	$ 2.26 B	France
AgeX Therapeutics AGE	5.36 M	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	29.5 M	-	-	$ 26.5 M	USA
Precision BioSciences DTIL	18.9 M	$ 4.33	3.1 %	$ 16.6 M	USA
AIkido Pharma AIKI	39.9 M	-	1.93 %	$ 17.4 M	USA
Agenus AGEN	314 M	$ 3.34	0.3 %	$ 1.2 M	USA
Dyadic International DYAI	5.88 M	$ 0.77	-1.68 %	$ 22.2 M	USA
Ayala Pharmaceuticals AYLA	7.77 M	-	-	$ 7.46 M	Israel
Editas Medicine EDIT	134 M	$ 2.15	-2.27 %	$ 177 M	USA
Edesa Biotech EDSA	1.98 M	$ 2.28	3.64 %	$ 7.29 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
Agios Pharmaceuticals AGIO	1.19 B	$ 29.2	-3.41 %	$ 1.69 B	USA
Advaxis ADXS	16.6 M	-	-9.65 %	$ 45.9 M	USA
Equillium EQ	22.6 M	$ 1.92	5.49 %	$ 66.7 M	USA